Difference between revisions of "Eberhart 2009 Leukemia"
Bader Helga (talk | contribs) |
Bader Helga (talk | contribs) |
||
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23: 2167- | |title=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23:2167-70. | ||
|info=[http://www.ncbi.nlm.nih.gov/pubmed/19657369 PMID: 19657369]; [http://www.nature.com/leu/journal/v23/n11/full/leu2009154a.html Open Access] | |info=[http://www.ncbi.nlm.nih.gov/pubmed/19657369 PMID: 19657369]; [http://www.nature.com/leu/journal/v23/n11/full/leu2009154a.html Open Access] | ||
|authors=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ | |authors=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ | ||
|year=2009 | |year=2009 | ||
|journal=Leukemia | |journal=Leukemia | ||
|abstract=Glucocorticoids (GCs) are an essential component of most chemotherapy protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (ALL).1, 2 Nevertheless, adverse side effects of GCs call for improved therapy protocols. | |||
GCs decrease the activity of glycolytic enzymes3 and upregulate the expression of the glycolytic regulator, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in vitro and in vivo.4 This led us to investigate whether co-administration of 2-deoxy-glucose (2-DG), an inhibitor of glycolysis, systemic application of which up to a blood concentration of approximately 3 mM had caused a transient hyperglycemia only,5 might potentiate the apoptotic effect of GC. | |||
}} | }} | ||
{{Labeling | {{Labeling | ||
Revision as of 14:22, 20 March 2015
| Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23:2167-70. |
Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Leukemia
Abstract: Glucocorticoids (GCs) are an essential component of most chemotherapy protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (ALL).1, 2 Nevertheless, adverse side effects of GCs call for improved therapy protocols.
GCs decrease the activity of glycolytic enzymes3 and upregulate the expression of the glycolytic regulator, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in vitro and in vivo.4 This led us to investigate whether co-administration of 2-deoxy-glucose (2-DG), an inhibitor of glycolysis, systemic application of which up to a blood concentration of approximately 3 mM had caused a transient hyperglycemia only,5 might potentiate the apoptotic effect of GC.
Labels:
Coupling state: OXPHOS
HRR: Oxygraph-2k
Labels
